Revolutionary molecule against lung cancer

Sadly aware of the fact that against lung cancer, which currently affects about 37,000 people every year in Italy alone, there are still few effective treatments, the pharmaceutical company Pharmion has announced the launch of an international phase III study on the treatment of small cell lung cancer with amrubicin (a new fully synthetic anthracycline). The study will be conducted internationally and will involve 480 patients. Researchers have high hopes in this trial as there are currently few therapies for this type of cancer. The trial intends to compare the action of the new molecule amrubicin with topotecan , the only chemotherapy drug approved (in the USA and in Europe) for the second-line treatment of small cell lung cancer. All that remains is to hope.